Previous Article Next Article

Muhammad Umair et al, 2018;1(2):66–76.

Frontonasal dysplasia: a review

Muhammad Umair1*, Farooq Ahmad1, Muhammad Bilal1, Muhammad Arshad2

Correspondence to: Muhammad Umair

*Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan.

Email: khugoo4u [at] yahoo.com, mumair [at] student.qau.edu.pk

Full list of author information is available at the end of the article.

Received: 23 March 2018 | Accepted: 12 May 2018


ABSTRACT

Frontonasal dysplasia (FND) is a rare complex genetic facial malformation, mostly characterized by affecting the face and head regions of the body. Craniofacial defects can have a severe impact, revealing different types of clinical phenotypes, which are broadly grouped as FNDs. FNDs have been classified along with selected disorders on the genetic and molecular basis. FND is clinically diagnosed on the basis of at least two features including median facial cleft, broad nasal bridge, ocular hypertelorism, widened philtrum, median cleft upper lip, widow’s peak frontal hairline, and missing or underdeveloped nasal tip. The three types of FNDs are caused by the ALX genes (ALX1, ALX3, and ALX4). Genes and pathways related to facial development are associated with direct or indirect expression of the FGF8, the Sonic hedgehog (SHH), and the BMP4. The present review provides a detail literature review on the FND phenotypes and mutation update of different genes involved that will help in proper classification, genetic counseling, and diagnosis of the affected families.


Keywords:

Frontonasal dysplasia, FND, ALX1, ALX3, ALX4.

Introduction

Frontonasal dysplasia (FND; MIM 136760) or median facial crack syndrome or frontonasal malformation was first described in 1967 (1), characterized by a primary defect in the medial portion of the face (2). Phenotypic features associated with the FND include ocular hypertelorism; median facial cleft, disturbing the nose and/or upper lip, broadening of the base of the nose; unilateral or bilateral side cleft or base of the nose; absent nasal tip; widow’s peak (frontal hairline) or V-shaped, ankyloglossia, and Poland’s syndactyly (24). Features such as ocular changes, mild to severe intellectual disability, and profound deafness have also been reported (5). However, the patients might possess a normal range of intelligence, misanthropy, shyness, and also aggressiveness (6,7).

FND is inherited in an autosomal recessive or autosomal dominant fashion. It has been reported independently (non-syndromic) or associated with other severe abnormalities (syndromic) (8). Isolated clinical symptoms are required for the prevalence of the FND, fissures in the midline of the face are observed in 1/100,000 live births (9) while the congenital nasal anomalies are observed in 1/20,000 or 1/40,000 live births (10). In the syndromic FNDs, the overlapping phenotypes can also cause difficulty in the clinical diagnosis. The present review provides a detail literature review on the three basic FNDs types along with few syndromic forms and providing mutation update, which will help in proper classification, molecular diagnosis, genetic counseling, and might explain the pleiotropy phenomenon.

Previously, two classification systems (The DE Myer classification system and the Sedano Jirasek classification) were used to characterize FND (1,2; (Supplementary Table 1)). Both these classification systems have their own merits and demerits. While, in the nosology and classification of genetic skeletal disorders 2015, FNDs were placed in group 34 (Dysostoses with predominant craniofacial involvement) along with oral-facial-digital syndrome type I (OFD1), Weyers acrofacial (acrodental) dysostosis, Mandibulo-facial dysostosis, Miller syndrome, Acrofacial dysostosis, Nager type, and Mandibulofacial dysostosis with microcephaly (Supplementary Table 1). Since disease-causing genes have been identified for both syndromic and non-syndromic FNDs, thus genetic and clinical classifications are more important to further understand the etiology underline FND.

Genes and Associated Syndromes

As FND is a highly heterogeneous disorder, so the associated syndromes are genetically diverse. There are several genes assorted with FND causing severe facial dimorphism. There have been few FND cases reported to date and molecular diagnosis still remains an important issue. Different factors might be responsible for the etiology of FND, as both genetic and environmental factors are contributing elements in causing such phenotypes. In the present literature review, genetic and clinical presentation of different FND types have been presented including different genes involved, which might help in proper classification and revealing the molecular mechanisms involved. Understanding the developmental and clinical aspects of the FND spectrum disorders will unravel different interesting aspects of proper diagnosis and treatment of FND. FND has been classified into three types FND type 1, 2, and 3. Detailed clinical presentation of FND types has been presented in Table 1.

Frontonasal dysplasia type 1 or frontorhiny (FND1; OMIM 606014)

The gene responsible for causing FND type 1 is ALX3 (Aristaless homeodomain 3; MIM 606014), located on chromosome 1p13.3. Twigg et al. (11) identified disease-causing homozygous variants in the ALX3 gene in seven families, thus named as FND type 1 (11). FND1 is inherited in an autosomal recessive manner and associated features include broad nasal root, median cleft lip/palate, tetralogy of Fallot, hypoplastic frontal sinuses, cranium bifidum occultum, mild to severe mental retardation, microphthalmia, conductive hearing loss, and cranium bifidum occultum (defect in midline frontal bone) (Figure 1), (11). Recently, Ullah et al. (4), reported mild phenotypes in a Pakistani family having ocular hypertelorism, absent nasal tip, widened philtrum, broad nasal bridge, widely spaced teeth, and having no intellectual disability (4).

ALX3 gene comprises a total of four exons, which encode 343-amino acids long homeodomain protein functioning as a transcriptional regulator. The ALX3 protein comprises a homeodomain and three proline-rich domains (Pro1, 2, 3). The amino-terminus consists of the Pro 1 and the Pro 2 while the Pro 3 is located at the carboxyl-terminus of the protein. Up till now, all the mutations have been reported in the homeodomain of the ALX3 protein suggesting a greater role of this domain in the frontorhiny pathogenesis (Figure 2). The ALX3 protein is mostly expressing in the neural crest-derived craniofacial mesenchyme and developing limbs. The alx3 knockout mice did not reveal any skeletal deformity; however, double mutant (alx3/alx4) mice exhibit severe craniofacial anomalies (12,13).

To date, eight pathogenic sequence variants have been reported in the ALX3 gene associated with frontorhiny in families from different ethnic regions (Pakistan, Ireland, Morocco, Netherland, Turkey, Algeria, and India). These include four missense mutations (c.608A>G; p.Asn203Ser (Algeria), c.502C>G; p.Leu168Val (Ireland), c. 547C>T; p.Arg183Trp (Netherlands), c.586C>T; p.Arg196Trp (India)), two nonsense mutations (c.543T>A; p.Try181* (Netherlands), c.604C>T; p.Gln202* (Pakistan)), one splice acceptor site (c.595-2A>T (Morocco)), and one frameshift variant (c.578_581 delCTGA; p.Thr193ArgfsX137 (Turkey)) (4,11). Classification according to the ethnic groups has been presented in Table 2.

Frontonasal dysplasia type 2 or FND2 (OMIM 605420)

Pathogenic sequence variants in the ALX4 (Aristaless homeodomain 4; MIM 605420) gene have been associated with FND2 (MIM 613451), having chromosomal location 11p11.2. FND2 is inherited in both autosomal recessive and autosomal dominant fashion with the identification of pathogenic ALX4 homozygous or heterozygous variants in several families. FND2 is associated with features such as hypertelorism, small head, short palpebral fissures, depressed nasal bridge, cleft nasal alae, bifid nasal tip, short, broad columella, alopecia (in some patients), sparse eyebrows, craniosynostosis, and intellectual disability (craniosynostosis in some patients) (Figure 1).

To date, 21 pathogenic mutations have been reported in the ALX4 gene including three homozygous mutations (c.793C>T; p.Arg265*, c.207delG, 2388bp incl ex. 4), causing FND2 (5,15) and 18 heterozygous mutations underlie parietal foramina permagna (OMIM 609597) including three nonsense (c.418C>T; p.Gln 140*, c.620C>A; p.Ser207*, c.736C>T; p.Gln246*) three missense (c.653G>A; p.Arg218Glu, c.815G>C; p.Arg272Pro, c.673C>G; p.Gln225Glu) three small deletions (c.385_394del10, c.504delT, c.291delG) one small insertion (c.343dupC) (1622). Two pathogenic mutations have also been associated with non-syndromic craniosynostosis (c.19G>T; p.Val7Phe, c.631A>G; p.Lys211Glu) (23), a single small deletion causing skull defects, alopecia, and hypertelorism (c.503delC) (14), and an 11.9 Mb gross deletion causing parietal foramen, in Potocki Schaffer syndrome (24), (Supplementary Table 2).

Frontonasal dysplasia type 3 (FND3; OMIM 601527)

FND type 3 (FND3) is a highly severe form of the FND. The affected individual’s exhibits complete failure of fusion between the frontonasal and maxillary arch-derived tissues, thus suffer from midfacial clefting (3,25). Loss of ALX1 (Aristaless homeodomain 1) function results in extreme bilateral microphthalmia, severe facial clefting, hypertelorism, disrupted palatal development, sparse eyelashes, absent eyebrows, mild mental retardation, and low-set posteriorly rotated ears (3,25; Figure 1). Both intragenic mutation and homozygous genomic deletion causing complete loss of function have been reported in the ALX1 gene resulting in severe to a mild manifestation of FND3. Recently, a homozygous splice acceptor site mutation has been reported having milder features, which might produce a truncated ALX1 protein harboring residual activity (3).

Table 1. Clinical presentation of different frontonasal dysplasias.

Figure 1. Clinical presentation for Frontonasal dysplasia (FND) types 1, 2, and 3.

Figure 2. Schematic representation of the ALX1, ALX3 and ALX4 gene and protein domains.

Table 2. FND1 classification according to mutations identified in different ethnic groups.

To date, only three mutations have been identified in the ALX3 gene including a homozygous 3.7 Mb deletion, an intergenic splice donor site variant (c.531+1G>A) causing FND in two different Turkish families and a biallelic splice acceptor site variant (c.661-1G>C) in a Pakistani family presenting mild FND phenotypes (3).

The ALX genes

The ALX genes possess a conserved Aristaless domain that is closely related to homeodomain-containing transcription factors. The mouse alx genes (alx1, alx3, and alx4) are mostly expressed in the frontonasal prominence (FNP) mesenchyme spanning stages of the mouse embryos, during which cells of the cranial neural crest migrate into the facial primordia (26). FND spectrum disorders are caused by mutations in the ALX genes and occur throughout the protein but are most specifically found in the homeodomain. The homeodomain exhibits homology with different related family members (27). Pathogenic loss of function mutations in the homeodomain class transcription factors is associated with severe human anomalies while the missense mutations within the homeodomain might be associated with DNA-binding activity pathogenesis (16,23,28).

Mega or gross deletions in the homeodomain of the ALX4 protein have also been reported to cause the FND phenotype (14,29). The genes alx1, alx3, and alx4 are expressed in the zebrafish facial mesenchyme cells; while the alx1 is also expressed in the neural crest cells (30). In a zebrafish embryos, reduced alx1 expression results in a severe phenotype such as severely hypoplastic facial skeleton, microphthalmia, and coloboma. While, the inhibition of alx3 expression did not reveal any abnormal facial phenotypes (30), thus signifying substantial functional differences between the alx genes, as alx1 expresses early relative to alx3 and alx4. Thus, alx1 has a greater role during the development of the zebrafish frontonasal structures. Loss of alx1 in mice causes failure of neural tube closure (midbrain) development and consequent loss of the skull vault, thus result in severe exencephalic phenotypes (31).

Syndromes Involving Frontonasal Phenotypes

Craniofrontonasal syndrome (CFNS; MIM 304110)

CFNS is a severe craniofacial syndrome inherited in X-linked dominant condition; thus, females are mostly affected exhibiting FND phenotypes such as bifid or hypoplastic nasal tip, severe hypertelorism, coronal craniosynostosis, longitudinally grooved or split nails, clavicle malformations, woolly or thick hairs. As CFNS is inherited in an X-linked dominant condition, thus prior to causative gene identification, there might be a modifier gene or embryonic lethality involved in males (3234). EFNB1 (ephrin B1) mutations have been identified in affected females while male having the same mutations in the EFNB1 gene presented milder phenotypes. The EFNB1 gene (NM_004429; MIM 300035) is located on chromosomal location Xq13.1 and encodes a 346 amino acids ephrin-B1 (NP_004420) protein. EFNB1 is a membrane ligand for the Eph receptor, involved in revolting signaling between individual cells (35). The X-chromosome inactivation phenomenon in the CFNS affected females is not observed, thus results in expression of either the wild-type or the mutant allele (35,36).

Features associated with EFNB1 pathogenesis include short stature, brachycephaly, frontal bossing, eyes abnormalities including hypertelorism, telecanthus, strabismus and nystagmus, broad nasal root, hypoplastic nasal tip, cleft lip/palate, syndactyly, brittle nails, grooved nails, developmental delay, and hypotonia (37). To date, 108 mutations have been reported in the EFNB1 gene including 105 mutations associated with the craniofrontonasal syndrome, two mutations associated with a diaphragmatic congenital hernia and single mutation causing hypertelorism (HGMD, 2017; http://www.hgmd.cf.ac.uk/ac/index.php).

Acromelic Frontonasal Dysostosis (AFND; MIM 603671)

AFND is a very severe disorder presenting severe craniofacial anomalies such as a median cleft face, widely spaced nasal alae, bifid nasal tip, hypertelorism, and parietal defects. It also includes several limb anomalies such as talipes equinovarus, underdeveloped tibia, and polydactyly. Features such as intellectual disability and brain malformations including corpus callosum agenesis, periventricular nodular heterotopia, interhemispheric lipoma, and hydrocephalus are also observed (3840). Pathogenic heterozygous de novo variant (c.3487C>T) in the ZSWIM6 gene (Zinc Finger SWIM-Type Containing 6; MIM 615951) has been reported as a cause of AFND (40,41). Deletions in the ZSWIM6 gene region have been observed in individuals with unrelated phenotypes as well (41). ZSWIM6 gene is located on chromosomal location 5q12.1, having 11 exons and encoding a 1,215 amino acids Zinc Finger SWIM-Type Containing six protein (42).

In a single family, a mild form of FND has been reported having a heterozygous deletion in the SIX2 gene (SIX homeobox 2; member of SIX gene family; a transcription factor) (43). The affected individual had features such as hypertelorism, frontal bossing with a large anterior fontanelle, flat nasal bridge, ptosis, bilateral parietal foramina, broad nasal tip, macrocephaly, and complete sagittal synostosis. AFND involves malformation of the skull, which is not characteristically related with FNP developmental defects. The facial skeleton and the anterior skull are shaped from direct ossification of neural crest progenitors while mesodermal precursors through endochondral ossification give rise to the skull base. However, Six2 mouse model involvement in the craniofacial development has demonstrated a relationship between these two independent structures (43).

Oral facial digital syndrome type I (OFD1; MIM 311200)

OFD1 is an X-linked dominant ciliopathy characterized by prominent features such as facial and oral malformations (oral clefts, cysts of the tongue, or hamartomas), and different types of digital anomalies (44). Abnormal dentition, polycystic kidney disease, thickened alveolar ridges, and absent lateral incisors are also observed in OFD1 patients. Although these features are easy to recognize in the affected individuals, and often lead to diagnosis in the early childhood.

Ferrante et al. (44) mapped several families to the critical region on Xp22 region and was able to identify pathogenic variants (a missense mutation, a 19-bp deletion, and a single basepair deletion leading to a frameshift in three families, a missense (de novo), a nonsense, a splice site, and a frameshift mutation in four sporadic patients) in the OFD1 gene (MIM 300170; also known as CXORF5) locate on chromosomal location Xp22.2, encoding a centriole and centriolar satellite OFD1 protein (44). Since the CXORF5 gene localizes to the basal body and centrosome of the primary cilia, OFD1 is considered as a ciliopathy disorder. Ferrante et al. (45) reported disturbance in the patterning process of the neural tube in the limb buds of mice lacking Ofd1, suggesting that Ofd1 might have an important role beyond primary cilium assembly and organization (45).

Pathogenic mutations in the CXORF5 gene have also been reported to cause Joubert syndrome-10 (JBTS10; MIM 300804), Simpson-Golabi-Behmel syndrome type 2 (GBS2; MIM 300209), and Retinitis pigmentosa 23 (MIM 300424). To date, 128 variants have been identified in the OFD1 (CXORF5) gene and 117 have been reported to cause oral-facial-digital syndrome type I, seven with Joubert syndrome, two with the oral-facial-digital syndrome, and single variant associated with X-linked retinitis pigmentosa and Simpson-Golabi-Behmel syndrome (HGMD; http://www.hgmd.cf.ac.uk/ac/index.php).

Acrofacial dysostosis type Nager (SF3B4; MIM 154400)

Nager syndrome or acrofacial dysostosis (MIM 154400), first described by Nager and De Reynier in 1948, belongs to a severe disorder of craniofacial and limb malformations. Slingenberg (46) characterized Nager syndrome as a group of disorders known as acrofacial dysostoses. The limb deformities include radial elements of the upper limbs (radioulnar synostosis), absent radius, phocomelia of the upper limbs, and the absence or hypoplasia of the thumbs. Nager acrofacial dysostosis has been reported to follow both autosomal recessive and dominant pattern of inheritance. The major facial features include midface retrusion, down-slanted palpebral fissures, and micrognathia, which often require the placement of a tracheostomy in early childhood (46).

Using whole exome sequencing in patients having Nager type of acrofacial dysostosis, Bernier et al. (47) identified 18 pathogenic heterozygous variants within the SF3B4 (splicing factor 3b subunit 4; MIM 605593) gene located on chromosome 1q21.2 (47). Another study also identified seven heterozygous variants including four de novo variants in their 12 patient’s analyzed (48). To date, 24 variants have been identified in the SF3B4 gene associated with the Nager syndrome including seven small insertions, two missense, five nonsense, nine small deletions, and a single splice site variant (HGMD). SF3B4 consists of six exons and encodes one of the four subunits of the splicing factor 3B protein having 424 amino acids.

Pathways Involved

Mechanisms such as patterning and growth of the facial primordia are associated with the expression of the FGF8 (fibroblast growth factor 8), the Sonic hedgehog (SHH), and the BMP4 (Bone morphogenetic protein 4). These key players have a vital role in patterning of the facial primordial, establishing growth, and any disturbance in these pathways might lead to severe facial clefting and FNP defects (4952). The SHH and FGF8 expression domains in the frontonasal ectoderm form a signaling midpoint known as the frontonasal ectodermal zone that morphogenetically directs the outcome of FNP development (52,53). In the patterning and outgrowth of FNP, the Bmp signaling, especially the BMP4, have a key role (54,55). It has been observed that any blockage in the Bmp signaling results in down-regulation of SHH in FNP and decrease the SHH ability to induce its own expression (52,56). Similarly, along with the SHH and BMPS pathways, the FGF signaling is required for normal proliferation of FNP mesenchyme, and any blockage in FGF signaling results in facial clefts (57). The efficiency of these signaling pathways in the patterning systems must be tightly regulated three-dimensionally. Time-based gene expression regulation and the proper distribution of different genes serve as markers for the facial primordial allowing a fine-scale analysis of such severe developmental defects. The frontonasal ectodermal zone patterning has been well described using the chicken embryo, where a failure of mid face outgrowth is observed when the distribution of FGF8 and SHH is disturbed (53,58). Similarly, using mouse embryos, the mid and upper facial patterning issues have been observed when distribution/regulation SHH/FGF8 is disturbed (58).

Conclusion

FND is a highly severe genetic condition having prominent features affecting the mid-facial and the frontal cranial skeleton. Increase in craniofacial volume is a result of epicanthal distance and the expanded skull vault, a fundamental process responsible for the development of these structures responsible for the loss of skeletal precursors and their derivatives. These processes are involved in uniting the complex architecture of the craniofacial skeleton. The complex presentation of FND involve a wide range of other severe developmental issues, thus, animal models are a right choice for understanding the complex pathogenesis of FND related genes. The advent of massively parallel sequencing technology such as next-generation sequencing including whole genome sequencing and careful clinical phenotyping has resulted in a quick diagnosis, especially for rare genetic disorders, which resulted in the identification of many new disease-causing genes (59,60). Hopefully, knowledge of the developmental mechanisms with a combination of these new technologies will lead to proper molecular and genetic characterization of the FND group in coming future.

Declaration of conflicting interests

The authors of this article have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

Funding

None.

Consent for publication

Not applicable

Ethical approval

Not applicable

Author details

Muhammad Umair1, Farooq Ahmad1, Muhammad Bilal1, Muhammad Arshad2

  1. Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
  2. Department of Bioinformatics and Biotechnology, International Islamic University, Islamabad, Pakistan.
  3. * Supplementary data available online.

References

  1. DeMyer W. The median cleft face syndrome. Differential diagnosis of cranium bifidum occultum, hypertelorism, and median cleft nose, lip, and palate. Neurology 1967; 17:961–71. https://doi.10.1212/WNL.17.10.961
  2. Sedano HO, Cohen MM Jr, Jirasek J, Gorlin RJ. Frontonasal dysplasia. J Pediatr 1970; 76:906–13.
  3. Ullah A, Kalsoom UE, Umair M, John P, Ansar M, Basit S, et al. Exome sequencing revealed a novel splice site variant in the ALX1 gene underlying frontonasal dysplasia. Clin Genet 2017; 91(3):494–8. https://doi.10.1111/cge.12822
  4. Ullah A, Umair M, Kalsoom UE, Basit S, Ahmad W. Exome sequencing revealed a novel nonsense variant in ALX3 Gene underlying frontorhiny. J Hum Genet 2018; 63(1):97–100. https://doi.10.1038/s10038-017-0358-y
  5. Kayserili H, Uz E, Niessen C, Vargel I, Alanay Y, Tuncbilek G, et al. ALX4 dysfunction disrupts craniofacial and epidermal development. Hum Mol Genet 2009; 18(22):4357–66. https://doi.10.1093/hmg/ddp391
  6. Pascual-Castroviejo I, Pascual-Pascual SI, Pérez-Higueras A. Fronto-nasal dysplasia and lipoma of the corpus callosum. Eur J Pediatr 1985; 144(1):66–71. https://doi.org/10.1007/BF00491930
  7. Antoneli MZ, Giacheti CM, Genaro KF, Zorzetto NL, Richieri-Costa A. Frontonasal dysplasia: clinical evaluation on audiological and brainstem electrophysiological profiles. Braz J Otorhinolaryngol 2011; 77(5):611–5. https://doi.org/10.1590/S1808-86942011000500013
  8. Mohammed SN, Swan MC, Wall SA, Wilkie AOM. Monozygotic twins discordant for frontonasal malformation. Am J Med Genet 2004; 130A:384–8. https:/doi:10.1002/ajmg.a.30280
  9. Rizvi M, Lypka MA, Kovacev T, Agris J. Median facial cleft dysmorphism in three siblings: case report and review of the literature. Cleft Palate Craniofac J 2010; 47(1):104–6. https://doi.10.1597/08-271
  10. Kean J, Al-Busaidi SS, Quaba AA. A case report of frontonasal dysplasia. Int J Pediatr Otorhinolaryngol 2010; 74(3):306–8. https://doi.10.1016/j.ijporl.2009.12.002
  11. Twigg SR, Versnel SL, Nurnberg G, Lees MM, Bhat M, Hammond P, et al. Frontorhiny, a distinctive presentation of frontonasal dysplasia caused by recessive mutations in the ALX3 homeobox gene. Am J Hum Genet 2009; 84:698–705. https://doi.10.1016/j.ajhg.2009.04.009
  12. Ten-Berge D, Brouwer A, el Bahi S, Guenet JL, Robert B, Meijlink F. Mouse Alx3: an aristaless-like homeobox gene expressed during embryogenesis in ectomesenchyme and lateral plate mesoderm. Dev Biol 1998; 199(1):
    11–25. https://doi.10.1006/dbio.1998.8921
  13. Beverdam A, Brouwer A, Reijnen M, Korving J, Meijlink F. Severe nasal clefting and abnormal embryonic apoptosis in Alx3/Alx4 double mutant mice. Development 2001; 128(20):3975–86.
  14. Kariminejad A, Bozorgmehr B, Alizadeh H, Ghaderi-Sohi S, Toksoy G, Uyguner ZO, et al. Skull defects, alopecia, hypertelorism, and notched alae nasi caused by homozygous ALX4 gene mutation. Am J Med Genet A 2014; 164A(5):1322–7. https://doi:10.1002/ajmg.a.36008
  15. Meloni VA, Moysés-Oliveira M, Melo MC, Caneloi TP, Dantas AG, Soares MF, et al. Novel homozygous ALX4 mutation causing frontonasal dysplasia-2 in a patient with meningoencephalocele. Clin Genet 2015; 88(6):593–6. https://doi.10.1111/cge.12595
  16. Wuyts W, Cleiren E, Homfray T, Rasore-Quartino A, Vanhoenacker F, Van Hul W. The ALX4 homeobox gene is mutated in patients with ossification defects of the skull (foramina parietalia permagna, OMIM 168500). J Med Genet 2000; 37(12):916–20. https://dx.doi.org/10.1136/jmg.37.12.916
  17. Mavrogiannis LA, Antonopoulou I, Baxová A, Kutílek S, Kim CA, Sugayama SM, et al. Haploinsufficiency of the human homeobox gene ALX4 causes skull ossification defects. Nat Genet 2001; 27(1):17, 8. https://doi.org/10.1038/83703
  18. Mavrogiannis LA, Taylor IB, Davies SJ, Ramos FJ, Olivares JL, Wilkie AO. Enlarged parietal foramina caused by mutations in the homeobox genes ALX4 and MSX2: from genotype to phenotype. Eur J Hum Genet 2006; 14(2):151–8. https://doi.org/10.1038/sj.ejhg.5201526
  19. Kayserili H, Altunoglu U, Ozgur H, Basaran S, Uyguner ZO. Mild nasal malformations and parietal foramina caused by homozygous ALX4 mutations. Am J Med Genet A 2012; 158A(1):236–44. https://doi.10.1002/ajmg.a.34390
  20. Bertola DR, Rodrigues MG, Quaio CR, Kim CA, Passos-Bueno MR. Vertical transmission of a frontonasal phenotype caused by a novel ALX4 mutation. Am J Med Genet A 2013; 161A(3):600–4. https://doi.10.1002/ajmg.a.35762
  21. Altunoglu U, Satkın B, Uyguner ZO, Kayserili H. Mild nasal clefting may be predictive for ALX4 heterozygotes. Am J Med Genet A 2014; 164A(8):2054–8. https://doi.10.1002/ajmg.a.36578
  22. El-Ruby M, El-Din Fayez A, El-Dessouky SH, Aglan MS, Mazen I, Ismail N, et al. Identification of a novel homozygous ALX4 mutation in two unrelated patients with frontonasal dysplasia type-2. Am J Med Genet A 2018; 176(5):1190–4. https://doi:10.1002/ajmg.a.38655
  23. Yagnik G, Ghuman A, Kim S, Stevens CG, Kimonis V, Stoler J, et al. ALX4 gain-of-function mutations in nonsyndromic craniosynostosis. Hum Mutat 2012; 33(12):1626–9. https://doi.10.1002/humu.22166
  24. Romeike BF, Wuyts W. Proximal chromosome 11p contiguous gene deletion syndrome phenotype: case report and review of the literature. Clin Neuropathol 2007; 26(1):1–11. https://doi.10.5414/NPP26001
  25. Uz E, Alanay Y, Aktas D, Vargel I, Gucer S, Tuncbilek G, et al. Disruption of ALX1 causes extreme microphthalmia and severe facial clefting: expanding the1spectrum of autosomal1recessive ALX1 related frontonasal dysplasia. Am J Hum Genet 2010; 86:789–96. https://doi.10.1016/j.ajhg.2010.04.002
  26. Beverdam A, Meijlink F. Expression patterns of group-I aristaless-related genes during craniofacial and limb development. Mech Dev 2001; 107(1–2):163–7. https://doi.org/10.1016/S0925-4773(01)00450-6
  27. D’Elia AV, Tell G, Paron I, Pellizzari L, Lonigro R, Damante G. Missense mutations of human homeoboxes: a review. Hum Mutat 2001; 18(5):361–74. https:/doi.10.1002/humu.1207
  28. Florisson JM, Verkerk AJ, Huigh D, Hoogeboom AJ, Swagemakers S, Kremer A, et al. Boston type craniosynostosis: report of a second mutation in MSX2. Am J Med Genet A 2013; 161A(10):2626–33. https://doi:10.1002/ajmg.a.36126
  29. Ferrarini A, Gaillard M, Guerry F, Ramelli G, Heidi F, Keddache CV, et al. Potocki-Shaffer deletion encompassing ALX4 in a patient with frontonasal dysplasia phenotype. Am J Med Genet A 2014; 164A(2):346–52. https://doi.10.1002/ajmg.a.36140
  30. Dee CT, Szymoniuk CR, Mills PE, Takahashi T. Defective neural crest migration revealed by a Zebrafish model of Alx1-related frontonasal dysplasia. Hum Mol Genet 2013; 22(2):239–51. https://doi.10.1093/hmg/dds423
  31. Zhao Q, Behringer RR, de Crombrugghe B. Prenatal folic acid treatment suppresses acrania and meroanencephaly in mice mutant for the Cart1 homeobox gene. Nat Genet 1996; 13(3):275–83. https://doi.org/10.1038/ng0796-275
  32. Sax CM, Flannery DB. Craniofrontonasal dysplasia: clinical and genetic analysis. Clin Genet 1996; 29(6):508–15. https://doi.org/10.1111/j.1399-0004.1986.tb00552.x
  33. Grutzner E, Gorlin RJ. Craniofrontonasal dysplasia: phenotypic expression in females and males and genetic considerations. Oral Sur Oral Med Oral Pathol Oral Radiol 1988; 65:436–44.
  34. Devriendt K, Van Mol C, Fryns JP. Craniofrontonasal dysplasia: more severe expression in the mother than in her son. J Genet Couns 1995; 6:361–64.
  35. Lisabeth EM, Falivelli G, Pasquale EB. Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol 2013; 5(9):a009159. https://doi. 10.1101/cshperspect.a009159
  36. Wieland I, Weidner C, Ciccone R, Lapi E, McDonald-McGinn D, Kress W, et al. Contiguous gene deletions involving EFNB1, OPHN1, PJA1 and EDA in patients with craniofrontonasal syndrome. Clin Genet 2007; 72:506–16. https://doi.org/10.1111/j.1399-0004.2007.00905.x
  37. Twigg SR, Babbs C, van den Elzen MEP, Goriely A, Taylor S, McGowan SJ, et al. Cellular interference in craniofrontonasal syndrome: males mosaic for mutations in the X-linked EFNB1 gene are more severely affected than true hemizygotes. Hum Molec Genet 2013; 22:
    1654–62. https://doi.10.1093/hmg/ddt015
  38. Verloes A, Gillerot Y, Walczak E, Van Maldergem L, Koulischer L. Acromelic frontonasal ‘dysplasia’: further delineation of a subtype with brain malformation and polydactyly (Toriello syndrome). Am J Med Genet 1992; 42:180–3. https://doi.10.1002/ajmg.1320420209
  39. Verloes A. Severe acrocallosal syndrome or acromelic frontonasal dysplasia? Am J Med Genet 1994; 50(3):306. https://doi.10.1002/ajmg.1320500320
  40. Slaney SF, Goodman FR, Eilers-Walsman BL, Hall BD, Williams DK, Young ID, et al. Acromelic frontonasal dysostosis. Am J Med Genet 1999; 83:109–16. https://doi.org/10.1002/(SICI)1096-8628(19990312)83
  41. Smith JD, Hing AV, Clarke CM, Johnson NM, Perez FA, Park SS, et al. Exome sequencing identifies a recurrent de novo ZSWIM6 mutation associated with acromelic frontonasal dysostosis. Am J Hum Genet 2014; 95:235–40. https://doi.10.1016/j.ajhg.2014.07.008
  42. Twigg SR, Ousager LB, Miller KA, Zhou Y, Elalaoui SC, Sefiani A, et al. Acromelic frontonasal dysostosis and ZSWIM6 mutation: phenotypic spectrum and mosaicism. Clin Genet 2016; 90(3):270–5. https://doi.10.1111/cge.12721
  43. Hufnagel RB, Zimmerman SL, Krueger LA, Bender PL, Ahmed ZM, Saal HM. A new frontonasal dysplasia syndrome associated with deletion of the SIX2 gene. Am J Med Genet A 2016; 170A(2):487–91. https://doi.10.1002/ajmg.a.37441
  44. Ferrante MI, Giorgio G, Feather SA, Bulfone A, Wright V, Ghiani M, et al. Identification of the gene for oral-facial-digital type I syndrome. Am J Hum Genet 2001; 68:569–76. https://doi.org/10.1086/318802
  45. Ferrante MI, Zullo A, Barra A, Bimonte S, Messaddeq N, Studer M, et al. Oral-facial-digital type I protein is required for primary cilia formation and left-right axis specification. Nat Genet 2006; 38(1):112–7. https://doi.org/10.1038/ng1684
  46. Slingenberg B. Misbildungen von Extremitaeten. Virchows Arc A Pathol Anat and Histol 1908; 193:1–92.
  47. Bernier FP, Caluseriu O, Ng S, Schwartzentruber J, Buckingham KJ, Innes AM, et al. Haploinsufficiency of SF3B4, a component of the pre-mRNA spliceosomal complex, causes Nager syndrome. Am J Hum Genet 2012; 90:925–33. https://doi.10.1016/j.ajhg.2012.04.004
  48. Czeschik JC, Voigt C, Alanay Y, Albrecht B, Avci S, Fitzpatrick D, et al. Clinical and mutation data in 12 patients with the clinical diagnosis of Nager syndrome. Hum Genet 2013; 132(8):885–98. https://doi.10.1007/s00439-013-1295-2
  49. Marcucio RS, Cordero DR, Hu D, Helms JA. Molecular interactions coordinating the development of the forebrain and face. Dev Biol 2005; 284(1):48–61. https://doi.10.1016/j.ydbio.2005.04.030
  50. Thomason HA, Dixon MJ, Dixon J. Facial clefting in Tp63 deficient mice results from altered Bmp4, Fgf8 and Shh signaling. Dev Biol 2008; 321(1):273–82. https://doi. 10.1016/j.ydbio.2008.06.030
  51. Parada C, Chai Y. Roles of BMP signaling pathway in lip and palate development. Front Oral Biol 2012; 16:60–70. https://doi.10.1159/000337617
  52. Hu D, Young NM, Li X, Xu Y, Hallgrímsson B, Marcucio RS. A dynamic Shh expression pattern, regulated by SHH and BMP signaling, coordinates fusion of primordia in the amniote face. Development 2015; 142(3):567–74. https://doi.10.1242/dev.114835
  53. Hu D, Marcucio RS, Helms JA. A zone of frontonasal ectoderm regulates patterning and growth in the face. Development 2003; 130(9):1749–58. https://doi. 10.1242/dev.00397
  54. Ashique AM, Fu K, Richman JM. Signalling via type IA and type IB bone morphogenetic protein receptors (BMPR) regulates intramembranous bone formation, chondrogenesis and feather formation in the chicken embryo. Int J Dev Biol 2002; 46(2):243–53. https://doi.10.1387/ijdb.011535
  55. Wu X, Walker J, Zhang J, Ding S, Schultz PG. Purmorphamine induces osteogenesis by activation of the hedgehog signaling pathway. Chem Biol 2004; 11(9):1229–38. https://doi.10.1016/j.chembiol.2004.06.010
  56. Foppiano S, Hu D, Marcucio RS. Signaling by bone morphogenetic proteins directs formation of an ectodermal signaling center that regulates craniofacial development. Dev Biol 2007; 312(1):103–14. https://doi. 10.1016/j.ydbio.2007.09.016
  57. Szabo-Rogers HL, Geetha-Loganathan P, Nimmagadda S, Fu KK, Richman JM. FGF signals from the nasal pit are necessary for normal facial morphogenesis. Dev Biol 2008; 318(2):289–302. https://doi.10.1016/j.ydbio.2008.03.027
  58. Hu D, Marcucio RS. A SHH-responsive signaling center in the forebrain regulates craniofacial morphogenesis via the facial ectoderm. Development 2009; 136(1):107–16. https://doi.10.1242/dev.026583
  59. Umair M, Alhaddad B, Rafique A, Jan A, Haack TB, Graf E, et al. Exome sequencing revealed a novel homozygous splice site variant in WNT1 gene underlying osteogenesis imperfecta type 3. Pediatr Res 2017; 82(5):753–8. https://doi.10.1038/pr.2017.149
  60. Umair M, Ullah A, Abbas S, Ahmad F, Basit S, Ahmad W. First direct evidence of involvement of a homozygous loss-of-function variant in the EPS15L1 gene underlying split-hand/split-foot malformation. Clin Genet 2018; 93(3):699–702. https://doi.10.1111/cge.13152
  61. Bonafe L, Cormier-Daire V, Hall C, Lachman R, Mortier G, Mundlos S, et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A 2015; 167A(12):2869–92. https://doi.10.1002/ajmg.a.37365
  62. Helbig KL, Farwell Hagman KD, Shinde DN, Mroske C, Powis Z, et al. Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy. Genet Med 2016; 18(9):898–905. https://doi.10.1038/gim.2015.186
  63. Xiong HY, Alipanahi B, Lee LJ, Bretschneider H, Merico D, Yuen RK, et al. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. Science 2015; 347(6218):1254806. https://doi.10.1126/science.1254806
  64. Gentile M, Wuyts W, Grittani S, Di Carlo A, Cariola F, Verdyck P, et al. Clinical, cytogenetic, and molecular characterization of a patient with a de novo interstitial 22q12 duplication. Am J Med Genet A 2004; 127A(2):186–90. https://doi.10.1002/ajmg.a.20672
  65. Farwell KD, Shahmirzadi L, El-Khechen D, Powis Z, Chao EC, Tippin Davis B, et al. Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions. Genet Med 2015; 17(7):578–86. https://doi.10.1038/gim.2014.154


This Article Cited By the following articles

Frontonasal dysplasia: A case report
Arch Craniofac Surg 2019; 20(6): 397.

1
 
Surgical Management of a Mild Case of Frontonasal Dysplasia: A Case Report and Review of Literature
2021; (): .

2
 
Multiple Cephalic Malformations in a Calf
Animals 2020; 10(9): 1532.

3